UMMS Affiliation

Division of Preventive and Behavioral Medicine

Publication Date

2019-05-01

Document Type

Article

Disciplines

Dermatology | Diagnosis | Epidemiology | Musculoskeletal Diseases | Skin and Connective Tissue Diseases

Abstract

BACKGROUND: Despite increasing awareness of the disease, rates of undiagnosed psoriatic arthritis (PsA) are high in patients with psoriasis (PsO). The validated Psoriasis Epidemiology Screening Tool (PEST) is a five-item questionnaire developed to help identify PsA at an early stage.

OBJECTIVES: To assess the risk of possible undiagnosed PsA among patients with PsO and characterize patients based on PEST scores.

METHODS: This study included all patients enrolled in the Corrona PsO Registry with data on all five PEST questions. Demographics, clinical characteristics and patient-reported outcomes were compared in Corrona PsO Registry patients with PEST scores > /=3 and < 3 using t-tests for continuous variables and chi-squared tests for categorical variables; scores > /=3 may indicate PsA.

RESULTS: Of 1516 patients with PsO, 904 did not have dermatologist-reported PsA; 112 of these 904 patients (12.4%) scored > /=3 and were significantly older, female, less likely to be working, and had higher BMI than patients with scores < 3. They also had significantly longer PsO duration, were more likely to have nail PsO and had worse health status, pain, fatigue, Dermatology Life Quality Index and activity impairment.

CONCLUSIONS: Improved PsA screening is needed in patients with PsO because the validated PEST identified over one-tenth of registry patients who were not noted to have PsA as having scores > /=3, who could have had undiagnosed PsA. Appropriate, earlier care is important because these patients were more likely to have nail PsO, worse health-related quality of life and worse activity impairment.

Rights and Permissions

© 2019 The Authors. This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.

DOI of Published Version

10.1111/jdv.15443

Source

J Eur Acad Dermatol Venereol. 2019 May;33(5):886-892. doi: 10.1111/jdv.15443. Epub 2019 Mar 5. Link to article on publisher's site

Journal/Book/Conference Title

Journal of the European Academy of Dermatology and Venereology : JEADV

Related Resources

Link to Article in PubMed

PubMed ID

30663130

Creative Commons License

Creative Commons Attribution-Noncommercial 4.0 License
This work is licensed under a Creative Commons Attribution-Noncommercial 4.0 License

Share

COinS
 
 

To view the content in your browser, please download Adobe Reader or, alternately,
you may Download the file to your hard drive.

NOTE: The latest versions of Adobe Reader do not support viewing PDF files within Firefox on Mac OS and if you are using a modern (Intel) Mac, there is no official plugin for viewing PDF files within the browser window.